Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.17 -0.01 (-0.24%)
price chart
Arena Pharmaceuticals, Inc. Earnings: Looking for More
Most biotech investor would be happy with 30% quarter-over-quarter prescription growth in a market that didn't grow much. But for Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq, the growth is coming off such a small base that it's hard to get too excited.
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows
Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 ...  MarketWatch
Related articles »  
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals' (NASDAQ: ARNA ) Belviq and VIVUS's (NASDAQ: VVUS ) Qsymia reported a combined 283,000 prescriptions ...
Arena And Vivus Investors Need To Watch Orexigen  Seeking Alpha (registration)
Related articles »  
Arena Pharmaceuticals, Inc., Loews Corporation, and Sysco Corporation ...
As Capitol Hill keeps its eyes closely trained on November elections, Wall Street's attention is elsewhere as earnings season continues this week.
Related articles »  
Why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is Rising?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) surged as much as 6.6%. It was a welcome reprieve for Arena shareholders, who had seen the stock lose 25% of its value this year before today's gains.
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
Geron Corp (NASDAQ:GERN) Skyrockets on Unusual Volume - Arena ...  StreetWise Report
Related articles »  
Arena Offers Tease On Belviq And Phentermine (ARNA)
Arena announced that the 12 week study involving 238 patients met the safety endpoints, but the company stopped short of announcing the results of weight loss, opting to save that data for the Obesity Week Conference next week.
Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot ...  MarketWatch
Related articles »  
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma ...
Arena Pharmaceuticals Inc.'s stock finished Tuesday's session 4.22% lower at $4.31. A total of 4.27 million shares were traded, which was below its three months average volume of 4.37 million shares.
Related articles »  
Closing Bell Stock Reports: Sotheby's (BID), Navient Corporation (NAVI), Arena ...
Arena Pharmaceuticals, Inc. (ARNA) changed by -0.24%, a change from open of- 1.650% at the close of today's trading.
Stocks in the Spotlight- SandRidge Energy Inc. (NYSE:SD), Arena ...  Techsonian (press release)
Related articles »  
Eisai Earnings Give Arena Investors Insights (ARNA)
Additional revenue for Arena can come from manufacturing services, other Eisai collaborative revenue, and the sale of Taigen stock that the company still holds. I anticipate that manufacturing revenue will be between $500,000 and $700,000. I anticipate ...
Stocks Worth Adding To Your Watchlist: Alpha Pro Tech, Ltd. (APT), Arena ...  Markets Emerging
Lorcaserin Data to be Presented at The Obesity Society's Annual ...  MarketWatch
Related articles »  
Will Belviq Advertising Pick Up Again?
The month of October has passed, and with that it is time to update on what has been happening on the advertising front with Belviq from Arena (NASDAQ:ARNA). Eight weeks ago the advertising for Belviq began running at a very impressive rate. Over the ...
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American ...
Related articles »  
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3. Last quarter, the company had posted a negative earnings surprise of 9.09%.
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected? - Analyst Blog  Nasdaq
Related articles »